Orphanet Journal of Rare Diseases | Social Pharmaceutical Innovations Addressing the Accessibility Challenges of Rare Disease Treatments

Recommend:

The study introduces a novel collaborative model called Social Pharmaceutical Innovations (SPIN), which enhances the availability, accessibility, and affordability of rare disease drugs by redefining stakeholder roles and adopting unconventional data collection approaches.

 

Literature Overview
This article, titled 'How social pharmaceutical innovations are addressing problems of availability, accessibility and affordability of drugs for rare diseases', published in the Orphanet Journal of Rare Diseases, reviews current challenges in the global rare disease drug development system and proposes a new pharmaceutical innovation model — Social Pharmaceutical Innovation (SPIN) — to address issues related to drug availability, accessibility, and affordability. The article notes that while some international measures (e.g., HTA collaboration and price negotiations) have improved rare disease treatments, their global impact remains uneven. It further highlights that SPINs offer more affordable treatment pathways by integrating multiple stakeholders, innovating data governance, and exploring new economic models.

Background Knowledge
Rare diseases affect approximately 473 million people globally, yet only about 4–5% of these diseases have approved therapies. Traditional pharmaceutical models, driven by market incentives, struggle to motivate companies to develop treatments for rare diseases, resulting in therapeutic shortages. Moreover, due to small patient populations, severity of the diseases, and lack of controls, traditional randomized clinical trials (RCTs) are difficult to conduct, hindering drug approval and reimbursement. Finally, high drug prices challenge the sustainability of healthcare systems. Based on 15 case studies from Brazil, Canada, France, and the Netherlands, this study analyses how SPINs can improve treatment accessibility through localized collaboration, unconventional data collection, and innovative payment mechanisms.

 

A tool that can be used to preliminarily predict the phenotypes that gene knockouts may produce before designing experiments.

Learn More

 

Research Methods and Experiments
The study uses a multiple-case analysis design, including 15 SPIN cases from Brazil, Canada, France, and the Netherlands. Data were collected through semi-structured interviews (151 in total), stakeholder meetings, and document analysis, and were validated during the 2023 Utrecht Global Conference. The research focuses on how SPINs redefine roles in drug development, market access, reimbursement, and pricing, and how they complement traditional pharmaceutical systems.

Key Findings and Perspectives

• SPINs redefine pharmaceutical innovation networks, enabling broader collaboration between governments, non-profits, patient groups, academic institutions, and companies.
• SPINs change traditional clinical data collection methods, such as in the CUREiHUS and CFDI projects, by replacing RCTs with real-world data and longitudinal studies to accelerate approval and reimbursement.
• SPINs explore localized manufacturing and non-patented drug preparation methods, such as magistral preparation in the Netherlands and the CLIC project in Canada, to reduce treatment costs and improve accessibility.
• SPINs introduce new payment and pricing mechanisms, such as risk-sharing agreements and cost-based pricing models, to address the issue of high drug prices.
• SPINs develop differently across countries, emphasizing the importance of local policies, institutions, and healthcare systems.

Significance and Future Directions
SPINs offer an innovative solution to systemic failures in rare disease treatment, particularly in localized knowledge integration, data governance, and unconventional economic models. Future research should focus on how to institutionalize SPINs so they become part of the mainstream pharmaceutical innovation system rather than remain on the margins. The study recommends strengthening multi-stakeholder collaboration, developing comprehensive data governance strategies, and designing sustainable economic models to support the scaling of SPIN initiatives.

 

A practical tool for rapidly mapping DNA or RNA sequences to the genome.

Learn More

 

Conclusion
This study systematically examines the implementation of Social Pharmaceutical Innovations (SPINs) in global rare disease treatment, emphasizing their potential to improve drug availability, accessibility, and affordability. Through 15 case studies, the authors demonstrate how SPINs reshape pharmaceutical innovation networks, change data collection practices, and open new treatment pathways for patients. The study notes that although SPINs are effective in specific contexts, their success depends on supportive local policies, institutions, and collaborative networks. Future efforts should focus on institutionalizing SPINs by promoting localized knowledge integration, developing data governance frameworks, and exploring sustainable economic models. Additionally, the study calls for increased international collaboration to drive the systemic improvement of treatment environments for rare disease patients.

 

Conor M W Douglas, Tineke Kleinhout-Vliek, Rob Hagendijk, Shir Grunebaum, and Ellen Moors. How social pharmaceutical innovations are addressing problems of availability, accessibility and affordability of drugs for rare diseases. Orphanet Journal of Rare Diseases.